A Risk-Benefit Assessment of Drugs Used in the Management of Obsessive-Compulsive Disorder
- 1 August 1996
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 15 (2) , 116-134
- https://doi.org/10.2165/00002018-199615020-00004
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Clomipramine versus Phenelzine in Obsessive–Compulsive DisorderThe British Journal of Psychiatry, 1992
- A Double-Blind Study of Adjuvant Buspirone Hydrochloride in Clomipramine-Treated Patients with Obsessive-Compulsive DisorderCurrent Opinion in Cardiology, 1992
- Lack of Efficacy of Lithium Augmentation in Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 1992
- Fenfluramine Augmentation of Clomipramine Treatment of Obsessive Compulsive DisorderAustralian & New Zealand Journal of Psychiatry, 1991
- Randomized Double-Blind Study of Fluvoxamine and Maprotiline in Treatment of DepressionPharmacopsychiatry, 1991
- Association of the Eosinophilia–Myalgia Syndrome with the Ingestion of TryptophanNew England Journal of Medicine, 1990
- Trazodone in the Treatment of Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 1987
- The Inheritance of Gilles de la Tourette's Syndrome and Associated BehaviorsNew England Journal of Medicine, 1986
- A multicenter controlled trial in phobic-obsessive psychoneurosis. The effect of chlorimipramine and of its combinations with haloperidol and diazepamProgress in Neuro-Psychopharmacology, 1981
- Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosisProgress in Neuro-Psychopharmacology, 1981